New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17β-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases

Journal of Medicinal Chemistry

Volumn 54, Issue 2, 2011, Pages 534-547

  Marchais Oberwinkler, Sandrine ^a   Wetzel, Marie ^a   Ziegler, Erika ^a   Kruchten, Patricia ^a   Werth, Ruth ^a   Henn, Claudia ^a   Hartmann, Rolf W ^a,b   Frotscher, Martin ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; NAPHTHALENE; NEW DRUG; PHENYL GROUP; TESTOSTERONE 17BETA DEHYDROGENASE; ZONISAMIDE;

ARTICLE; BREAST CANCER; CELL ASSAY; CONTROLLED STUDY; DRUG METABOLISM; DRUG PENETRATION; ENDOMETRIOSIS; HUMAN; HUMAN CELL; IC 50; MALE; MEMBRANE TRANSPORT; NONHUMAN; RAT; SUZUKI REACTION;

17-HYDROXYSTEROID DEHYDROGENASES; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; CELL-FREE SYSTEM; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; HUMANS; LIVER; MALE; MICROSOMES; MOLECULAR MIMICRY; NAPHTHOLS; PHENOLS; PLACENTA; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECOMBINANT PROTEINS; STEROIDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78751651034     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1009082     Document Type: Article

References (68)

1. Liehr, J. G. Is estradiol a genotoxic mutagenic carcinogen? Endocr. Rev. 2000, 21, 40-54
2. Thomas, D. B. Do hormones cause breast cancer? Cancer 1984, 53, 595-604
3. Russo, J.; Fernandez, S. V.; Russo, P. A.; Fernbaugh, R.; Sheriff, F. S.; Lareef, H. M.; Garber, J.; Russo, I. H. 17beta-Estradiol induces transformation and tumorigenesis in human breast epithelial cells FASEB J. 2006, 20, 1622-1634
4. Dizerega, G. S.; Barber, D. L.; Hodgen, G. D. Endometriosis: role of ovarian steroids in initiation, maintenance, and suppression Fertil. Steril. 1980, 33, 649-653
5. Zeitoun, K.; Takayama, K.; Sasano, H.; Suzuki, T.; Moghrabi, N.; Andersson, S.; Johns, A.; Meng, L.; Putman, M.; Carr, B.; Bulun, S. E. Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol J. Clin. Endocrinol. Metab. 1998, 83, 4474-4480
6. Gobbi, S.; Cavalli, A.; Rampa, A.; Belluti, F.; Piazzi, L.; Paluszcak, A.; Hartmann, R. W.; Recanatini, M.; Bisi, A. Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme J. Med. Chem. 2006, 49, 4777-4780
7. Le Borgne, M.; Marchand, P.; Duflos, M.; Delevoye-Seiller, B.; Piessard-Robert, S.; Le Baut, G.; Hartmann, R. W.; Palzer, M. Synthesis and in vitro evaluation of 3-(1-azolylmethyl)-1 H -indoles and 3-(1-azolyl-1- phenylmethyl)-1 H -indoles as inhibitors of P450 arom Arch. Pharm. (Weinheim, Ger.) 1997, 330, 141-145
8. Jacobs, C.; Frotscher, M.; Dannhardt, G.; Hartmann, R. W. 1-Imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthase and aromatase J. Med. Chem. 2000, 43, 1841-1851
9. Baston, E.; Hartmann, R. W. N -Substituted 4-(5-indolyl)benzoic acids. Synthesis and evaluation of steroid 5alpha-reductase type I and II inhibitory activity Bioorg. Med. Chem. Lett. 1999, 9, 1601-1606
10. Picard, F.; Baston, E.; Reichert, W.; Hartmann, R. W. Synthesis of N -substituted piperidine-4-(benzylidene-4-carboxylic acids) and evaluation as inhibitors of steroid-5alpha-reductase type 1 and 2 Bioorg. Med. Chem. 2000, 8, 1479-1487
11. Picard, F.; Schulz, T.; Hartmann, R. W. 5-Phenyl substituted 1-methyl-2-pyridones and 4′-substituted biphenyl-4-carboxylic acids. synthesis and evaluation as inhibitors of steroid-5alpha-reductase type 1 and 2 Bioorg. Med. Chem. 2002, 10, 437-448
12. Aggarwal, S.; Thareja, S.; Verma, A.; Bhardwaj, T. R.; Kumar, M. An overview on 5alpha-reductase inhibitors Steroids 2010, 75, 109-153
13. Speirs, V.; Green, A. R.; Atkin, S. L. Activity and gene expression of 17beta-hydroxysteroid dehydrogenase type I in primary cultures of epithelial and stromal cells derived from normal and tumourous human breast tissue: the role of IL-8 J. Steroid Biochem. Mol. Biol. 1998, 67, 267-274
14. Gunnarsson, C.; Ahnström, M.; Kirschner, K.; Olsson, B.; Nordenskjöld, B.; Rutqvist, L. E.; Skoog, L.; Stäl, O. Amplification of HSD17B1 and ERBB2 in primary breast cancer Oncogene 2003, 22, 34-40
15. Šmuc, T.; Hevir, N.; Ribic̈-Pucelj, M.; Husen, B.; Thole, H.; Lanišnik Riz̈ner, T. Disturbed estrogen and progesterone action in ovarian endometriosis Mol. Cell. Endocrinol. 2009, 301, 59-64
16. Suzuki, T.; Miki, Y.; Nakamura, Y.; Moriya, T.; Ito, K.; Ohuchi, N.; Sasano, H. Sex steroid-producing enzymes in human breast cancer Endocr.-Relat. Cancer 2005, 12, 701-720 (Pubitemid 41815772)
17. Chetrite, G. S.; Cortes-Prieto, J.; Philippe, J. C.; Wright, F.; Pasqualini, J. R. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues J. Steroid Biochem. Mol. Biol. 2000, 72, 23-27
18. Husen, B.; Huhtinen, K.; Poutanen, M.; Kangas, L.; Messinger, J.; Thole, H. Evaluation of inhibitors for 17beta-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme Mol. Cell. Endocrinol. 2006, 248, 109-113
19. Husen, B.; Huhtinen, K.; Saloniemi, T.; Messinger, J.; Thole, H. H.; Poutanen, M. Human hydroxysteroid (17beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts Endocrinology 2006, 147, 5333-5339
20. Day, J. M.; Foster, P. A.; Tutill, H. J.; Parsons, M. F. C.; Newman, S. P.; Chander, S. K.; Allan, G. M.; Lawrence, H. R.; Vicker, N.; Potter, B. V. L.; Reed, M. J.; Purohit, A. 17beta-Hydroxysteroid dehydrogenase type 1, and not type 12, is a target for endocrine therapy of hormone-dependent breast cancer Int. J. Cancer 2008, 122, 1931-1940
21. Kruchten, P.; Werth, R.; Bey, E.; Oster, A.; Marchais-Oberwinkler, S.; Frotscher, M.; Hartmann, R. W. Selective inhibition of 17beta-hydroxysteroid dehydrogenase type 1 (17betaHSD1) reduces estrogen responsive cell growth of T47-D breast cancer cells J. Steroid Biochem. Mol. Biol. 2009, 114, 200-206
22. Moeller, G.; Adamski, J. Multifunctionality of human 17beta- hydroxysteroid dehydrogenases Mol. Cell. Endocrinol. 2006, 248, 47-55
23. Azzi, A.; Rehse, P. H.; Zhu, D. W.; Campbell, R. L.; Labrie, F.; Lin, S. X. Crystal structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase complexed with 17 beta-estradiol Nature Struct. Biol. 1996, 3, 665-668
24. Breton, R.; Housset, D.; Mazza, C.; Fontecilla-Camps, J. C. The structure of a complex of human 17beta-hydroxysteroid dehydrogenase with estradiol and NADP+ identifies two principal targets for the design of inhibitors Structure 1996, 4, 905-915
25. Gangloff, A.; Shi, R.; Nahoum, V.; Lin, S. Pseudosymmetry of C19 steroids, alternative binding orientations, and multispecificity in human estrogenic 17beta-hydroxysteroid dehydrogenase FASEB J. 2003, 17, 274-276
26. Ghosh, D.; Pletnev, V. Z.; Zhu, D. W.; Wawrzak, Z.; Duax, W. L.; Pangborn, W.; Labrie, F.; Lin, S. X. Structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase at 2.20 Å resolution Structure 1995, 3, 503-513
27. Han, Q.; Campbell, R. L.; Gangloff, A.; Huang, Y. W.; Lin, S. X. Dehydroepiandrosterone and dihydrotestosterone recognition by human estrogenic 17beta-hydroxysteroid dehydrogenase. C-18/C-19 steroid discrimination and enzyme-induced strain J. Biol. Chem. 2000, 275, 1105-1111
28. Mazza, C.; Breton, R.; Housset, D.; Fontecilla-Camps, J. C. Unusual charge stabilization of NADP+ in 17beta-hydroxysteroid dehydrogenase J. Biol. Chem. 1998, 273, 8145-8152
29. Qiu, W.; Zhou, M.; Labrie, F.; Lin, S. Crystal structures of the multispecific 17beta-hydroxysteroid dehydrogenase type 5: critical androgen regulation in human peripheral tissues Mol. Endocrinol. 2004, 18, 1798-1807
30. Sawicki, M. W.; Erman, M.; Puranen, T.; Vihko, P.; Ghosh, D. Structure of the ternary complex of human 17beta-hydroxysteroid dehydrogenase type 1 with 3-hydroxyestra-1,3,5,7-tetraen-17-one (equilin) and NADP+ Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 840-845
31. Mazumdar, M.; Fournier, D.; Zhu, D.; Cadot, C.; Poirier, D.; Lin, S. Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy Biochem. J. 2009, 424, 357-366
32. Poirier, D. Inhibitors of 17 beta-hydroxysteroid dehydrogenases Curr. Med. Chem. 2003, 10, 453-477
33. Day, J. M.; Tutill, H. J.; Purohit, A.; Reed, M. J. Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis Endocr.-Relat. Cancer 2008, 15, 665-692
34. Broz̈ic, P.; Lanišnik Riz̈ner, T.; Gobec, S. Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 Curr. Med. Chem. 2008, 15, 137-150
35. Poirier, D. Advances in development of inhibitors of 17beta hydroxysteroid dehydrogenases Anticancer Agents Med. Chem. 2009, 9, 642-660
36. Poirier, D. 17beta-Hydroxysteroid dehydrogenase inhibitors: a patent review Expert Opin. Ther. Pat. 2010, 20, 1123-1145
37. Day, J. M.; Tutill, H. J.; Purohit, A. 17b-Hydroxysteroid dehydrogenase inhibitors Minerva Endocrinol. 2010, 35, 87-108
38. Marchais-Oberwinkler, S.; Henn, C.; Möller, G.; Klein, T.; Negri, M.; Oster, A.; Spadaro, A.; Werth, R.; Wetzel, M.; Xu, K.; Frotscher, M.; Hartmann, R. W.; Adamski, J. 17β-Hydroxysteroid dehydrogenases (17β-HSD): novel therapeutic targets, protein structures and recent progress in inhibitor development. J. Steroid Biochem. Mol. Biol. in press.
39. Deluca, D.; Krazeisen, A.; Breitling, R.; Prehn, C.; Möller, G.; Adamski, J. Inhibition of 17beta-hydroxysteroid dehydrogenases by phytoestrogens: comparison with other steroid metabolizing enzymes J. Steroid Biochem. Mol. Biol. 2005, 93, 285-292
40. Messinger, J.; Hirvelä, L.; Husen, B.; Kangas, L.; Koskimies, P.; Pentikainen, O.; Saarenketo, P.; Thole, H. New inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 Mol. Cell. Endocrinol. 2006, 248, 192-198
41. Lilienkampf, A.; Karkola, S.; Alho-Richmond, S.; Koskimies, P.; Johansson, N.; Huhtinen, K.; Vihko, K.; Wähälä, K. Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3- d ]pyrimidin-4(3 H)-one core J. Med. Chem. 2009, 52, 6660-6671
42. Bey, E.; Marchais-Oberwinkler, S.; Kruchten, P.; Frotscher, M.; Werth, R.; Oster, A.; Algül, O.; Neugebauer, A.; Hartmann, R. W. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases Bioorg. Med. Chem. 2008, 16, 6423-6435 (Pubitemid 351783414)
43. Bey, E.; Marchais-Oberwinkler, S.; Werth, R.; Negri, M.; Al-Soud, Y. A.; Kruchten, P.; Oster, A.; Frotscher, M.; Birk, B.; Hartmann, R. W. Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) J. Med. Chem. 2008, 51, 6725-6739
44. Al-Soud, Y. A.; Bey, E.; Oster, A.; Marchais-Oberwinkler, S.; Werth, R.; Kruchten, P.; Frotscher, M.; Hartmann, R. W. The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17beta-hydroxysteroid dehydrogenase (17beta-HSD) type 1 and type 2 Mol. Cell. Endocrinol. 2009, 301, 212-215
45. Bey, E.; Marchais-Oberwinkler, S.; Negri, M.; Kruchten, P.; Oster, A.; Klein, T.; Spadaro, A.; Werth, R.; Frotscher, M.; Birk, B.; Hartmann, R. W. New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity J. Med. Chem. 2009, 52, 6724-6743
46. Oster, A.; Klein, T.; Werth, R.; Kruchten, P.; Bey, E.; Negri, M.; Marchais-Oberwinkler, S.; Frotscher, M.; Hartmann, R. W. Novel estrone mimetics with high 17beta-HSD1 inhibitory activity Bioorg. Med. Chem. 2010, 18, 3494-3505
47. Frotscher, M.; Ziegler, E.; Marchais-Oberwinkler, S.; Kruchten, P.; Neugebauer, A.; Fetzer, L.; Scherer, C.; Müller-Vieira, U.; Messinger, J.; Thole, H.; Hartmann, R. W. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases J. Med. Chem. 2008, 51, 2158-2169 (Pubitemid 351503271)
48. Marchais-Oberwinkler, S.; Kruchten, P.; Frotscher, M.; Ziegler, E.; Neugebauer, A.; Bhoga, U.; Bey, E.; Müller-Vieira, U.; Messinger, J.; Thole, H.; Hartmann, R. W. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics J. Med. Chem. 2008, 51, 4685-4698
49. Marchais-Oberwinkler, S.; Frotscher, M.; Ziegler, E.; Werth, R.; Kruchten, P.; Messinger, J.; Thole, H.; Hartmann, R. W. Structure-activity study in the class of 6-(3′-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors Mol. Cell. Endocrinol. 2009, 301, 205-211
50. Bhatt, M. V.; Kulkarni, S. U. Cleavage of Ethers Synthesis 1983, 1983, 249-282
51. Miyaura, N.; Suzuki, A. Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds Chem. Rev. 1995, 95, 2457-2483
52. Mewshaw, R. E.; Edsall, R. J.; Yang, C.; Manas, E. S.; Xu, Z. B.; Henderson, R. A.; Keith, J. C.; Harris, H. A. ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity J. Med. Chem. 2005, 48, 3953-3979
53. Koubachi, J.; El Kazzouli, S.; Berteina-Raboin, S.; Mouaddib, A.; Guillaumet, G. Synthesis of Polysubstituted Imidazo[1,2- a ]pyridines via Microwave-Assisted One-Pot Cyclization/Suzuki Coupling/Palladium-Catalyzed Heteroarylation J. Org. Chem. 2007, 72, 7650-7655
54. Carreño, M.; García Ruano, J.; Sanz, G.; Toledo, M.; Urbano, A. Orthobromination of phenols predominates in CS2 Synlett 1997, 1997, 1241-1242
55. Qiu, W.; Campbell, R. L.; Gangloff, A.; Dupuis, P.; Boivin, R. P.; Tremblay, M. R.; Poirier, D.; Lin, S. A concerted, rational design of type 1 17beta-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affinity FASEB J. 2002, 16, 1829-1831
56. Kruchten, P.; Werth, R.; Marchais-Oberwinkler, S.; Frotscher, M.; Hartmann, R. W. Development of a biological screening system for the evaluation of highly active and selective 17beta-HSD1-inhibitors as potential therapeutic agents Mol. Cell. Endocrinol. 2009, 301, 154-157
57. Hidalgo, I. J. Assessing the absorption of new pharmaceuticals Curr. Top. Med. Chem. 2001, 1, 385-401
58. Pillon, A.; Boussioux, A.; Escande, A.; Aït-Aïssa, S.; Gomez, E.; Fenet, H.; Ruff, M.; Moras, D.; Vignon, F.; Duchesne, M.; Casellas, C.; Nicolas, J.; Balaguer, P. Binding of estrogenic compounds to recombinant estrogen receptor-alpha: application to environmental analysis Environ. Health Perspect. 2005, 113, 278-284
59. Zhu, B. T.; Han, G.; Shim, J.; Wen, Y.; Jiang, X. Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: insights into the structural determinants favoring a differential subtype binding Endocrinology 2006, 147, 4132-4150
60. Ahmad, S.; Doweyko, L.; Ashfaq, A.; Ferrara, F. N.; Bisaha, S. N.; Schmidt, J. B.; DiMarco, J.; Conder, M. L.; Jenkins-West, T.; Normandin, D. E.; Russell, A. D.; Smith, M. A.; Levesque, P. C.; Lodge, N. J.; Lloyd, J.; Stein, P. D.; Atwal, K. S. Tetrahydronaphthalene-derived amino alcohols and amino ketones as potent and selective inhibitors of the delayed rectifier potassium current IKs Bioorg. Med. Chem. Lett. 2004, 14, 99-102
61. Zhang, P.; Kern, J. C.; Terefenko, E. A.; Trybulski, E. J. 5-Aryl-indan-1-ol and analogs useful as progesterone receptor modulators. U.S. Patent Appl US2009/0325916A1, Dec 31, 2009.
62. Puranen, T. J.; Poutanen, M. H.; Peltoketo, H. E.; Vihko, P. T.; Vihko, R. K. Site-directed mutagenesis of the putative active site of human 17 beta-hydroxysteroid dehydrogenase type 1 Biochem. J. 1994, 304 (Pt 1) 289-293
63. Lin, S. X.; Yang, F.; Jin, J. Z.; Breton, R.; Zhu, D. W.; Luu-The, V.; Labrie, F. Subunit identity of the dimeric 17 beta-hydroxysteroid dehydrogenase from human placenta J. Biol. Chem. 1992, 267, 16182-16187
64. Sam, K. M.; Auger, S.; Luu-The, V.; Poirier, D. Steroidal spiro-gamma-lactones that inhibit 17 beta-hydroxysteroid dehydrogenase activity in human placental microsomes J. Med. Chem. 1995, 38, 4518-4528
65. Sam, K. M.; Boivin, R. P.; Tremblay, M. R.; Auger, S.; Poirier, D. C16 and C17 derivatives of estradiol as inhibitors of 17 beta-hydroxysteroid dehydrogenase type 1: chemical synthesis and structure-activity relationships Drug Des. Discovery 1998, 15, 157-180
66. Zimmermann, J.; Liebl, R.; von Angerer, E. 2,5-Diphenylfuran-based pure antiestrogens with selectivity for the estrogen receptor alpha J. Steroid Biochem. Mol. Biol. 2005, 94, 57-66
67. Hartmann, R. W. Influence of alkyl chain ramification on estradiol receptor binding affinity and intrinsic activity of 1,2-dialkylated 1,2-bis(4- or 3-hydroxyphenyl)ethane estrogens and antiestrogens J. Med. Chem. 1986, 29, 1668-1674
68. Yee, S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man - fact or myth Pharm. Res. 1997, 14, 763-766